efavirenz has been researched along with Metabolic Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohn, S; Currier, J; Koletar, S; McCutchan, J; Murphy, R; Williams, P; Wu, J | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Nolan, D | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Calmy, A; Carey, DL; Carr, A; Cooper, DA; Emery, S; Law, MG; Samaras, K; Wand, H | 1 |
| De Villar, NG; Estrada, V; Fernández, C; Larrad, MT; López, AG; Serrano-Rios, M | 1 |
2 review(s) available for efavirenz and Metabolic Syndrome
| Article | Year |
|---|---|
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
2 trial(s) available for efavirenz and Metabolic Syndrome
| Article | Year |
|---|---|
Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Body Fat Distribution; Cardiovascular Diseases; Coronary Disease; Cyclopropanes; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Immune Reconstitution Inflammatory Syndrome; Male; Metabolic Syndrome; Middle Aged; Treatment Outcome | 2009 |
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Constitution; Cardiovascular Diseases; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Progression; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2007 |
2 other study(ies) available for efavirenz and Metabolic Syndrome
| Article | Year |
|---|---|
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Oxazines; Phenotype; Protease Inhibitors | 2002 |